Tag

Amyloid Beta

All articles tagged with #amyloid beta

science1 day ago•8 min saved

Alcohol Triggers Opposite Brain Signals in Alzheimer’s Pathways

A Texas A&M study found that alcohol interacts with Alzheimer’s-related brain changes in a pathology-dependent way: in amyloid-beta models, alcohol reduces corticostriatal signaling and disrupts microglia responses, while in tau models it increases signaling along the same circuit. This challenges the idea of a simple additive risk and suggests individual brain responses to alcohol may hinge on a person’s specific pathology and disease stage.

via Neuroscience News|

#alcohol #alzheimers-disease #amyloid-beta

science7 days ago•2 min saved

Cognitive Flexibility May Act as Early Hint for Alzheimer’s, Study Finds

A Nature Communications study using 5xFAD mice shows cognitive flexibility is impaired before memory deficits, linked to hyperactivity in the medial prefrontal cortex; silencing overactive neurons reduces amyloid-beta accumulation and partially restores flexibility, suggesting a potential route to earlier Alzheimer’s diagnosis.

via Nautilus | Science|

#alzheimers-disease #amyloid-beta #cognitive-flexibility

science18 days ago•5 min saved

Copper drug reboots brain cleanup pumps to cut Alzheimer's proteins in mice

A copper-containing drug Cu(ATSM) boosted brain P-glycoprotein pumps, increased clearance of amyloid-beta by about 42%, and improved spatial memory by about 44% over 56 days in Alzheimer's-model mice, suggesting a potential preclinical approach to restore brain waste clearance, though human trials and safety assessments remain essential.

via ScienceAlert|

#alzheimers-disease #amyloid-beta #cuatsm

health24 days ago•3 min saved

Copper Drug Reboots Brain Cleanup, Reduces Alzheimer's Toxins and Restores Memory in Lab Study

Monash University researchers report in ACS Chemical Neuroscience that the copper compound Cu(ATSM) strengthens the brain's waste-clearing system by boosting P-glycoprotein pumps at the blood-brain barrier in an Alzheimer's model, reducing amyloid-beta by 42% and improving spatial memory by about 44% over 56 days, pointing to a therapy for neurovascular dysfunction; Cu(ATSM) has safety data from other neurological conditions, potentially speeding human testing, though exact clearance pathways and microglial involvement require further study.

via ScienceDaily|

#alzheimers-disease #amyloid-beta #blood-brain-barrier

science28 days ago•5 min saved

GRK2: A Fresh Target for Alzheimer’s Therapy Shows Promise in Mice

Scientists identify the enzyme GRK2, and its inactive form, as a new target in Alzheimer's disease. In mouse models and some human brain tissue, inactive GRK2 accumulates with mitochondria, boosting amyloid-beta production and harming mitochondrial function. The compound dubbed Compound 10 prevents GRK2 from clumping, restoring mitochondrial health, reducing amyloid-beta, and slowing dementia progression in mice, marking a potential new therapeutic avenue that still needs validation in humans.

via ScienceAlert|

#alzheimers #amyloid-beta #compound-10

science1 month ago•8 min saved

GRK2-targeting Compound 10 slows Alzheimer’s progression in mouse models

ETH Zurich researchers identified that inactivated GRK2 aggregates in dementia brains damage mitochondrial function and accelerate amyloid-beta production, creating a self-perpetuating cycle. They developed Compound 10 to prevent GRK2 aggregation, which improved mitochondrial energy, reduced amyloid-beta, and extended survival in Alzheimer’s mouse models, with additional systemic anti-aging benefits observed. The basic research is complete and a patent has been filed; industry partnership is sought to advance toward clinical development.

via Neuroscience News|

#alzheimers-disease #amyloid-beta #compound-10

science1 month ago•7 min saved

Microglial State Switch Reveals Dual Paths to Alzheimer’s Resilience

A human-brain study identifies six tissue domains and a pivotal transition in microglia from an amyloid-associated inflammatory state to a tau-associated antigen-presenting state; resilience against dementia arises via two routes—octogenarians who block progression and centenarians whose late microglial activation is uncoupled from tau—pointing to therapies that preserve early microglial responses or target pathways like TREM2 to delay cognitive decline.

via Neuroscience News|

#alzheimers-disease #amyloid-beta #microglia

science1 month ago•5 min saved

Nanoparticles Restore Brain Cleanup, Reversing Alzheimer’s Signs in Mice

Researchers used supramolecular nanoparticles that act as drugs to repair the brain's blood-brain barrier and restart its waste-clearance system. In mice with high amyloid-β, three injections reduced brain Aβ by 50–60% within an hour, with months-long vascular and cognitive improvements; the approach leverages the LRP1 transport system to reset clearance. While promising, the work is in animal studies and human trials remain years away.

via ScienceDaily|

#alzheimers-disease #amyloid-beta #blood-brain-barrier

science1 month ago•10 min saved

Common amino acid arginine slows Alzheimer’s pathology in animals

Japanese researchers found that arginine, a safe and inexpensive amino acid, reduced amyloid-β aggregation, decreased brain inflammation, and improved behavior in fruit flies and mice models of Alzheimer’s disease. The effects appear to come from interfering with protein misfolding rather than lowering production. While promising and eligible for repurposing, the work is preclinical and dosing differs from dietary supplements, so larger preclinical and human studies are needed before clinical use.

via SciTechDaily|

#alzheimers-disease #amyloid-beta #arginine

health-and-medicine2 months ago•6 min saved

Affordable Arg: Arginine Slows Alzheimer’s Damage in Animal Models

A Kindai University study shows that the inexpensive amino acid arginine can reduce amyloid-β buildup and brain inflammation in Alzheimer’s models (flies and mice), improving behavior; given its safety and low cost, arginine could be a rapid candidate for repurposing, but human trials and optimal dosing are still needed.

via ScienceDaily|

#alzheimers-disease #amyloid-beta #arginine

science2 months ago•35 min saved

Midlife clues reveal Alzheimer’s may start decades before memory loss

A Mayo Clinic study finds Alzheimer’s-related changes can begin in people’s late 50s, decades before memory problems, outlining a two-phase timeline where amyloid buildup appears first, followed by other biomarkers and cognitive changes as people age, with blood and imaging signals peaking later. The research warns that averages don’t predict an individual's onset and suggests earlier, smarter screening and planning, while noting limitations in population diversity and the need for clearer clinical guidelines.

via Earth.com|

#aging #alzheimers #amyloid-beta

health2 months ago•5 min saved

GLP-1 diabetes medicines show potential to curb Alzheimer's protein buildup in preclinical studies

A new review of mostly preclinical studies links GLP-1 diabetes/weight-loss medications (e.g., semaglutide, liraglutide) to reduced amyloid-beta plaques and tau tangles in cells and animals, with only two small human trials reporting mixed results; still early evidence and larger clinical trials are needed to confirm cognitive benefits.

via ScienceAlert|

#alzheimers-disease #amyloid-beta #clinical-trials

science2 months ago•6 min saved

GLP-1 Diabetes Drugs Target Alzheimer’s Pathology in Animal Studies

A systematic review of 30 preclinical studies finds GLP-1 receptor agonists (liraglutide, semaglutide, exenatide, dulaglutide) consistently reduce Alzheimer's hallmarks amyloid-beta plaques and tau tangles in animal and cell models, with liraglutide showing the strongest and most consistent effects; human data are limited and mixed so far, though some trials show preserved brain glucose metabolism and inflammatory marker changes, suggesting these drugs may help prevent dementia if used earlier rather than cure established disease.

via Neuroscience News|

#alzheimers-disease #amyloid-beta #glp-1-receptor-agonists

health2 months ago•2 min saved

Amyloid-Targeting Alzheimer’s Drugs Show No Meaningful Benefit and Increase Brain Risks

A Cochrane review of 17 trials (20,342 participants) finds anti-amyloid drugs for Alzheimer’s disease do not provide clinically meaningful cognitive or daily-function benefits in mild cognitive impairment or mild dementia and may raise risks of brain swelling and bleeding, despite removing amyloid-beta from the brain. The evidence suggests these drugs do not translate into patient benefit, prompting a shift toward exploring other treatment pathways.

via Cochrane Collaboration|

#alzheimers-disease #amyloid-beta #anti-amyloid-drugs

science2 months ago•7 min saved

Intracellular Tug-of-War Between Amyloid Beta and Tau Redefines Alzheimer's Cause

UC Riverside researchers propose that Alzheimer’s disease may arise from a competition inside neurons where amyloid beta and tau vie for the same microtubule binding sites, disrupting intracellular transport; this could mean plaques are a downstream effect rather than the root cause and shift therapy toward preventing this intracellular interference or boosting protein clearance.

via SciTechDaily|

#alzheimers-disease #amyloid-beta #microtubules